Enzyme And Application Thereof

ABSTRACT

Provides an artificial enzyme obtained by improving upon a sequence of a natural nicotine dehydrogenase, wherein the improvement comprises replacing at least one amino acid hindering product release with an amino acid with smaller side chains, thereby improving a catalytic rate.

FIELD OF THE INVENTION

The present invention belongs to the field of protein engineering and relates to a protein mutant, in particular to a nicotine dehydrogenase mutant and application thereof in areas such as for developing protein drug for treating nicotine addiction.

DESCRIPTION OF THE PRIOR ART

Nicotine (1-methyl-2-[3-pyridine]-pyrrolidine) is one of main harmful ingredients in tobacco leaves, cigarette smoke and tobacco waste, which is harmful to human health and is an important precursor of nitrosamine (TSNA) that is the main carcinogenic ingredient in tobacco. In China, a great amount of tobacco with a high nicotine content is produced in the tobacco production each year, which not only affects smoking quality of tobacco seriously, but also increases harmfulness of tobacco. Therefore, reducing the contents of nicotine in tobacco and environment is of extremely important significance to maintain human health and to protect ecological environment. The degradation of nicotine by microorganisms is a new approach to reduce contents of nicotine in tobacco and environment and nicotine's harmfulness, especially Pseudomonas and Arthrobacter can metabolize and decompose nicotine to generate the essential carbon source, nitrogen source and energy for their growth. Bacteria which have been discovered to be able to metabolize nicotine include Pseudomonas (for example, Pseudomonas sp.No.41, P.convexa PCl, P.putida), Arthobacter (for example, Arthrobacter oxidans P-34, which was re-identified as A. ureafaciens; A. oxidans pAO1 later, and then was re-identified as Arthrobacter nicotinoborans later), Cellulomonas sp., and Ochrobactrum intermedium. The fungi mainly include Cunninghamella echinulata, Microsporum gypseum, Streptomyces griseus, S. platenses and Pelliculariafilamentosa.

It has been found that microbial metabolism of nicotine is mainly through three pathways: Pyridine pathway (mainly in Arthrobacter sp), Pyrrolidine pathway (mainly in Pseudomonas sp.) and Me pathway (mainly existing in the fungi). In the Pyrrolidine pathway, the pyrrole ring of nicotine is oxidized to produce methylmyosmine, and when water is added, ring opening of methylmesamine occurs to form pseudooxynicotine, which is further demethylated to form 3-carboxylic acid pyridinium salt, and the 6′ position of the pyridine ring is re-hydroxylated to form a 6-hydroxy, 3-carboxylic acid pyridinium salt, and after side chain is removed, 2, 5-dihydroxy-pyridinium salt and succinate salt are formed. This metabolic pathway can also start with 6-hydroxy pseudooxynicotine, and eventually 2, 5-dihydroxy-pyridinium salt and succinate salt are produced.

The nicotine dehydrogenase NicA2 is an enzyme recently isolated from Pseudomonas putida S16 that can degrade nicotine. The reports related to nicotine dehydrogenase NicA2 can be found in: PLoS Genet. 2013 October; 9(10): e1003923. doi: 10.1371/joumal.pgen. 1003923. Epub 2013 Oct 24. Systematic unraveling of the unsolved pathway of nicotine degradation in Pseudomonas. Tang H, Wang L, Wang W, Yu H, Zhang K, Yao Y, Xu P.

In the first step of dehydrogenation reaction of nicotine degradation catalyzed by Nicotine dehydrogenase NicA2, nicotine (I) is converted to N-methymyosmine (II), which can further be subjected to a spontaneous hydration reaction to produce pseudooxynicotine (III).

NicA2 is encoded by nicA2 gene, and plays a crucial role in the degradation pathway of nicotine metabolized by Pseudomonas putida S16. When the nicA2 gene is knocked out, Pseudomonas putida S16 cannot grow with nicotine as the sole carbon and nitrogen source (PLoS Genet. 10.1371/joumal. pgen. 1003923).

NicA2 belongs to the family of monoamine oxidase (MAO). MAO mainly exists on the outer membrane of mitochondria and its main role in the organism is to catalyze the metabolism of endogenous and exogenous monoamines. Under the action of MAO, monoamines are oxidized to generate deamination. MAO can be divided into two categories, i.e., MAO-A and MAO-B, according to substrates, distribution locations, and selective inhibitors for MAO. MAO-A has high affinity for serotonin (5-HT), norepinephrine (NE) and dopamine (DA) (J. Mol. Biol 338, 103-114); and MAO-B has high affinity for phenethyl amines (PEA) and benzylamine, etc. (Proc. Natl Acad. Sci. USA 100, 9750-9575).

In the initiation of nicotine degradation by Pseudomonas putida, NicA2 catalyzes nicotine to produce pseudooxynicotine, providing the initial impetus for the entire metabolic pathway. Research on the nicotine metabolic pathway by Xu Ping's Research Group has confirmed that subsequent 6-hydroxy-3-succinylpyridine monooxygenase (HspB) and 2,5-dihydroxypyridine dioxygenase (HPO) can further catalyze deacidification and ring opening of nicotine, to form a simple structure, which finally enters the tricarboxylic acid cycle (J. Biol. Chem. 42: 29158-29170; Sci. Rep./3-3235/D01:10.1038/srep03235). Therefore, the first step of processing of nicotine by NicA2 initiates efficient operation of the subsequent enzyme catalysis and even the entire metabolic pathway. The catalytic efficiency of NicA2 is the key point for determining the whole metabolic efficiency for nicotine and is a key factor for the construction of subsequent metabolic pathways. The article “A new strategy for smoking cessation: characterization of a bacterial enzyme for the degradation of nicotine” published in JACS in 2015 initially reported the possibility of NicA2 for treating cigarette addiction. The report points out that NicA2 has high efficiency and stability for the catalysis of substrate nicotine, and even in the mouse serum, NicA2 can maintain a high activity at 37° C. In addition, NicA2 has high affinity for the substrate nicotine, which catalyzes the degradation of nicotine with a K_(m) value of 91.9 nM, while the highest nicotine content in blood is between 162 and 370 nM. So, theoretically, if NicA2 can successfully function in degradation of nicotine in human body, then the nicotine content in the human body is in a saturated level for NicA2. The key for developing protein drugs with nicotine dehydrogenase is the high-efficiency nicotine dehydrogenase. The higher the activity of the enzyme is, the lower the amount of developed drug is and the better the effect is. The wild type enzyme has limitation in a catalytic rate. If the enzyme can be modified by a protein engineering method to increase its catalytic efficiency, the development and utilization of nicotine dehydrogenase can be greatly facilitated.

Therefore, those skilled in the art are directed to developing a nicotine dehydrogenase with a high catalytic rate and its application in the biocatalysis, metabolic engineering modifications, and protein drug development.

SUMMARY OF THE INVENTION

In view of the foregoing drawbacks of the prior art, the technical problem to be solved by the present invention is to modify a nicotine dehydrogenase to obtain a nicotine dehydrogenase with a high catalytic rate and application thereof.

In order to achieve the above objects, in one aspect, the present invention provides an artificial enzyme.

In one particular embodiment of the present invention, the artificial enzyme is manufactured by modifying a sequence of a natural enzyme, wherein the natural enzyme has the activity for catalyzing the conversion reaction from compound I to compound II, as shown by the following formula,

or, the natural enzyme is nicotine dehydrogenase;

wherein the modification comprises: substituting at least one of the amino acids that block product release with amino acids with smaller side chains.

Further, the natural enzyme has one or more of the following features:

1) the amino acid sequence of the natural enzyme includes amino acid sequence with more than 85%, or more than 90%, or more than 95%, or more than 98%, or more than 99% homology to the amino acid sequence shown in SEQ ID NO:1; or the amino acid sequence of the natural enzyme includes the amino acid sequence shown in SEQ ID NO:1; or the amino acid sequence of the natural enzyme is as shown in SEQ ID NO:1;

2) the natural enzyme is encoded by nucleic acid hybridized with complementary chain of nucleic acid encoding protein with an amino acid sequence shown by SEQ ID NO:1 under a high stringent condition; and

3) the natural enzyme exists in the microorganism Pseudomonas.

Further, the natural enzyme exists in Pseudomonas putida S16.

Further, the natural enzyme has a product release channel for product release, the amino acid whose side chains are located in the product release channel of the natural enzyme includes at least one of tryptophan, tyrosine, phenylalanine, glutamic acid and methionine; and the above modification comprises: substituting at least one of the tryptophan, tyrosine, phenylalanine, glutamic acid and methionine whose side chains are located in product release channel of natural enzyme with amino acids with smaller side chains.

Further, there are at least 9 amino acids whose side chains are located in product release channel of the natural enzyme, and the 9 amino acids are selected from tryptophan, tyrosine, phenylalanine, glutamic acid and methionine.

Further, the three-dimensional structure of the natural enzyme at least comprises one β-sheet and one α-helix located at the release channel, 3 of the 9 amino acids are located at the β-sheet, according to the relative positions, the 3 amino acids are phenylalanine at position 353, phenylalanine at position 355 and tryptophan at position 364 respectively; 6 of the 9 amino acids are located at α-helix, according to the relative positions, the 6 amino acids are the phenylalanine at position 163, tyrosine at position 214, tyrosine at position 218, tyrosine at position 242, methionine at position 246 and glutamic acid at position 149, respectively.

Further, the substituting modes are: if the amino acid to be substituted is located on β-sheet, the amino acid is substituted with valine; if the amino acid to be substituted is located on α-helix, the amino acid is substituted with alanine.

Preferably, the modification comprises: substituting all amino acids that block product release and have a molecular weight of more than 120 with amino acids with smaller side chains.

In another aspect, the present invention provides an enzyme, and in one particular embodiment, the enzyme has one or more of the following features:

1) the amino acid sequence of the enzyme includes amino acid sequence with more than 85%, or more than 90%, or more than 95%, or more than 98%, or more than 99% homology to the amino acid sequence shown in SEQ ID NO: 2; or the amino acid sequence of the enzyme includes the amino acid sequence shown in SEQ ID NO: 2; or the amino acid sequence of the enzyme is as shown in SEQ ID NO: 2;

2) the enzyme is encoded by nucleic acid hybridized with complementary chain of nucleic acid encoding protein with an amino acid sequence shown by SEQ ID NO: 2 under a high stringent condition; and

3) the amino acid sequence of the enzyme includes the amino acid sequence in which the amino acid sequence as shown in SEQ ID NO: 2 is conservatively substituted; wherein, according to the relative positions, at least one of the amino acids at positions 353, 355 and 364 of the enzyme is a first small-molecular-weight amino acid; at least one of the amino acids at positions 163, 214, 218, 242, 246 and 249 of the enzyme is a second small-molecular-weight amino acid, and the first small-molecular-weight amino acid has a molecular weight less than 140, and the second small-molecular-weight amino acid has a molecular weight less than 110.

Further, the enzyme has the activity for catalyzing the conversion reaction from compound I to compound II as shown by the following formula:

or, the enzyme is nicotine dehydrogenase.

Further, the amino acids at positions 353, 355 and 364 are located in β-sheet; and the amino acids at positions 163, 214, 218, 242, 246 and 249 are located in α-helix. Further, the first small-molecular-weight amino acid is valine, and the second small-molecular-weight amino acid is alanine.

Preferably, the amino acids at positions 353, 355 and 364 are all first small-molecular-weight amino acids, and the amino acids at positions 163, 214, 218, 242, 246 and 249 are all second small-molecular-weight amino acids.

In still another aspect, the present invention provides an enzyme, and in one particular embodiment, the enzyme has the activity for catalyzing the conversion reaction from compound Ito compound II as shown by the following formula:

or, the enzyme is nicotine dehydrogenase.

The enzyme has a product release channel for product release, and the amino acid with side chains located at the narrowest site of the product release channel has a molecular weight of less than 140.

Preferably, the amino acid with side chains located at the narrowest site of the product release channel has a molecular weight of less than 120.

Preferably, the amino acid with side chains located at the narrowest site of the product release channel is valine or alanine.

In another aspect, the present invention provides a nucleotide sequence that encodes the artificial enzyme or enzyme.

Further, the nucleotide sequence has one or more of the following features:

1) the nucleotide sequence includes the nucleotide sequence with more than 85%, or more than 90%, or more than 95%, or more than 98%, or more than 99% homology to the nucleotide sequence shown in SEQ ID NO:3; or the nucleotide sequence includes the nucleotide sequence shown in SEQ ID NO:3; or the nucleotide sequence is as shown in SEQ ID NO:3; and

2) the nucleotide sequence can be hybridized with complementary chain of nucleotide sequence shown by SEQ ID NO:3 under a high stringent condition.

In still another aspect, the present invention provides an expression vector or a host cell containing the above nucleotide sequence.

In still another aspect, the present invention provides application of the above artificial enzyme or the enzyme in degradation of nicotine.

The present invention further provides application of the above artificial enzyme or the enzyme in preparation of drugs for treating nicotine addiction.

The present invention further provides use of the above artificial enzyme or the enzyme in preparation of enzyme preparations for biocatalytic conversion.

The present invention further provides application of the above artificial enzyme or the enzyme in metabolic engineering modifications and synthetic biology.

In still another aspect, the present invention provides a method for modifying enzymes of monoamine oxidase family, wherein the method comprises: substituting at least one of the amino acids that block product release with amino acids with smaller side chains.

In the present invention, the crystal structure analysis is performed by protein engineering methods starting from wild-type nicotine dehydrogenase, to obtain the relevant structure that affects product release, and influence of related amino acids on the product release is eliminated by means of amino acid substitution, thereby improving the catalytic rate of mutant enzyme. In a preferred embodiment of the invention, although the affinity of the nicotine dehydrogenase mutant is slightly weaker than that of the wild-type nicotine dehydrogenase, the nicotine dehydrogenase mutant's rate for catalyzing the substrate nicotine is much higher than that of wild-type nicotine dehydrogenase, that is, 3.67 times.

The present invention firstly analyzes the structure of nicotine dehydrogenase and obtains a binding structure of nicotine dehydrogenase and substrate nicotine. 9 large amino acid residues hindering product release are obtained through analysis on the foregoing structure and related experiments, which lays a solid foundation for the subsequent mutation to obtain nicotine dehydrogenase with high catalytic efficiency. In addition, the foregoing 9 large amino acid residues that hinder product release have certain conservation among other members of the monoamine oxidase family, laying a good basis for modifying members of the monoamine oxidase family.

The nicotine dehydrogenase mutant of the present invention can be applied at least in biocatalysis, metabolic engineering and synthetic biology as well as development of protein drugs, with promising commercial application prospects:

(a) biocatalysis: the nicotine dehydrogenase mutant obtained in the present invention has superior catalytic properties than natural nicotine dehydrogenase, which can be used to acquire higher catalytic properties for catalyzing nicotine into a product, and thus, it can be used for development of enzyme preparations for biocatalysis conversion;

(b) metabolic engineering and synthetic biology: the above obtained mutant can perform the same catalytic reactions as the natural nicotine dehydrogenase, but it has higher catalytic efficiency, thus it can be used in metabolic engineering modifications and synthetic biology for the development of efficient metabolic pathways, to improve the nicotine transformation ability of strains; and

(c) development of protein drugs: the above obtained mutant can be used to transform nicotine to eventually produce pseudooxynicotine and have higher catalytic conversion ability than natural proteins, so the mutant can be used for efficient transformation of nicotine in blood, and thereby for developing drugs related to treatment of nicotine addiction.

The concept, specific steps and technical effects of the present invention are further described in conjunction with the accompanying drawings, so as to fully illustrate the objects, features and effects of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a polyacrylamide gel electrophoresis pattern of purified NicA2 protein according to a preferred embodiment of the present invention, wherein, Lane 1: supernatant after bacteria lysis; Lane 2: precipitate after bacteria lysis; Lane 3: column effluent; Lane 4: 20 mM imidazole washing liquid; Lane 5: 50 mM imidazole washing liquid; Lane 6: 80 mM imidazole eluate; Lane 7: 170 mM imidazole eluate; Lane 8: 300 mM imidazole eluate; and M: protein molecular weight marker.

FIG. 2 shows an optimized crystal of a NicA2 protein after being subjected to crystal primary screening, optimization through precipitating agent, seed adding, truncation of amino acid sequence, and adjustment of a ratio of protein to crystallization reagent according to a preferred embodiment of the present invention. The presence of FAD makes the crystal a bright yellow color.

FIG. 3 shows a structural diagram of a NicA2Δ20-nicotine crystal according to a preferred embodiment of the present invention. a: when viewing the product release channel from above, no product is observed from the outer surface of the crystal structure, indicating that the product is completely embedded by NicA2; b: when viewing the product release channel from above after adjusting the gray scale to transparent, the product release channel is blocked by 9 large amino acids; and c: it is a cross section of the product release channel.

FIG. 4 shows a polyacrylamide gel electrophoresis pattern of purified NicA2-M9 protein according to a preferred embodiment of the present invention, wherein, Lane 1: supernatant after bacteria lysis; Lane 2: precipitate after bacteria lysis; Lane 3: column effluent; Lane 4: 20 mM imidazole lotion; Lane 5: 50 mM imidazole for removing impurity protein; Lane 6: target protein eluted by 170 mM imidazole; and M: protein molecular weight marker.

FIG. 5 shows a Michaelis-Menten equation curve for the process of the production of N-methylmyosmine by catalyzing nicotine with wild type NicA2 according to a preferred embodiment of the present invention.

FIG. 6 shows a Michaelis-Menten equation curve for the process of the production of pseudooxynicotine by catalyzing nicotine with wild type NicA2 according to a preferred embodiment of the present invention.

FIG. 7 shows a Michaelis-Menten equation curve for the process of the production of N-methylmyosmine by catalyzing nicotine with NicA2-M9 according to a preferred embodiment of the present invention.

FIG. 8 shows a Michaelis-Menten equation curve for the process of the production of pseudooxynicotine by catalyzing nicotine with NicA2-M9 according to a preferred embodiment of the present invention.

FIG. 9 shows the release amount of pseudooxynicotine detected by GC according to a preferred embodiment of the present invention.

FIG. 10 shows cross-sectional views of product release channels of five NicA2 mutants generated in a particular embodiment of the present invention and wild type NicA2, wherein, A: wild type NicA2; B: NicA2-M3V mutant; C: NicA2-M3A mutant; D: NicA2-M5 mutant; E: NicA2-M7 mutant; and F: NicA2-M9 mutant.

FIG. 11 shows cross-sectional views of product release channels of 12 NicA2 mutants generated in a particular embodiment of the present invention and wild-type NicA2, wherein, A: wild-type NicA2; G: NicA2-M3G6A mutant; H: NicA2-M4G5A mutant; I: NicA2-M5G4A mutant; J: NicA2-M3P6A mutant; K: NicA2-M4P5A mutant; L: NicA2-M5P4A mutant; M: NicA2-M3S6A mutant; N: NicA2-M4S5A mutant; O: NicA2-M5S4A mutant; P: NicA2-M3T6A mutant; Q: NicA2-M4T5A mutant; R: NicA2-M5T4A mutant.

FIG. 12 shows the results of comparison of the amino acid sequence of NicA2 with that of the protein of monoamine oxidase family.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

One aspect of the present invention provides an artificial enzyme manufactured by modifying a sequence of a natural enzyme.

The artificial enzyme used herein should be understood as any enzyme that has been modified for natural enzymes, including genetic engineering modifications, for example, enzyme mutants.

The natural enzyme has the activity for catalyzing the conversion reaction from compound Ito compound II as shown by the following formula.

Or, the natural enzyme is nicotine dehydrogenase.

The enzyme described herein having the activity for catalyzing the above reaction should be understood as not only an enzyme which specifically catalyze the above reaction, but also an enzyme which do not specifically catalyze the above reaction, for example, in addition to catalyzing the above reaction, an enzyme that can catalyze the dehydrogenation of 6-hydroxy nicotine (including D type and L type).

The “nicotine dehydrogenase” used herein refers to an enzyme capable of catalyzing the dehydrogenation of a pyrrole ring of a nicotine or nicotine analog (for example, 6-hydroxy nicotine).

The modification comprises: substituting at least one of the amino acids that block product release with amino acids with smaller side chains.

As used herein, “amino acids that block product release” should be understood as any amino acid which can increase product release efficiency or enzyme catalytic efficiency by substitution with other amino acids. For example, if the side chain of an amino acid is located in a product release channel or pathway and the product release efficiency or catalytic efficiency of the enzyme can be increased after the amino acid is substituted with an amino acid with smaller side chains, the amino acid is “an amino acid that blocks product release”.

As a preferred particular embodiment, the natural enzyme has one or more of the following features:

1) the amino acid sequence of the natural enzyme includes amino acid sequence with more than 85%, or more than 90%, or more than 95%, or more than 98%, or more than 99% homology to the amino acid sequence shown in SEQ ID NO:1; or the amino acid sequence of the natural enzyme includes the amino acid sequence shown in SEQ ID NO:1; or the amino acid sequence of the natural enzyme is as shown in SEQ ID NO:1;

2) the natural enzyme is encoded by nucleic acid hybridized with complementary chain of nucleic acid encoding protein with an amino acid sequence shown by SEQ ID NO:1 under a high stringent condition; and

3) the natural enzyme exists in the microorganism Pseudomonas. “Homology” as used herein may refer to an optimal comparison of sequences (nucleotides or amino acids), and the comparison can be performed using a computerized implementation of an algorithm. For example, “homology” associated with a polynucleotide can be obtained by perform analysis with BLASTN version 2.0 based on default parameters. “Homology” associated with a polypeptide (i.e., an amino acid) can be determined by a program (e.g. BLASTP version 2.2.2) based on default parameters. The program compares the polypeptides or fragments being compared (or compares nucleotide fragments), to determine the degree of amino acid identity or similarity.

“Hybridization under conditions of low stringency, medium stringency, high stringency, or very high stringency” as used herein describes the hybridization and washing conditions. The guidance for performing hybridization reactions can refer to Current Protocols in Molecular Biology, John Wiley&Sons, N.Y. (1989), 6.3.1-6.3.6. The document describes the aqueous and non-aqueous methods, and either of which can be used. The specific hybridization conditions herein are as follows: 1) low stringency hybridization conditions: hybridization at about 45° C. in 6× sodium chloride/sodium citrate (SSC), and then washing at least twice at 50° C. in 0.2×SSC, and 0.1% SDS (the washing temperature should be raised to 55° C. for low stringency conditions); 2) medium stringency hybridization conditions: hybridization at about 45° C. in 6×SSC, and then washing once or multiple times at 60° C. in 0.2×SSC, and 0.1% SDS; 3) high stringency hybridization conditions: hybridization at about 45° C. in 6×SSC, and then washing once or multiple times at 65° C. in 0.2×SSC, and 0.1% SDS; and 4) extremely high stringency hybridization conditions: hybridization at 65° C. in 0.5 M sodium phosphate, and 7% SDS, and then washing once or multiple times at 65° C. in 0.2×SSC, and 0.1% SDS. The high stringency conditions (3) are preferred and should be used unless otherwise stated.

As a more preferred particular embodiment, the natural enzyme exists in the Pseudomonas putida S16, which has a preservation number CCTCC NO. M 205038, and is preserved in China Center for Type Culture Collection on Apr. 18, 2005. In addition, the strain is also preserved in Deutsche Sammlung von Mikroorganismen and Zellkulturen (DSMZ), with a preservation number of DSM 28022.

As a preferred particular embodiment, the natural enzyme has a product release channel, the amino acid whose side chains are located in the product release channel of natural enzyme includes at least one of the tryptophan, tyrosine, phenylalanine, glutamic acid and methionine; and the modification comprises: substituting at least one of the tryptophan, tyrosine, phenylalanine, glutamic acid and methionine whose side chains are located in product release channel of the natural enzyme with amino acids with smaller side chains.

The “product release channel” used herein should be understood as a path that a product needs to pass from leaving the reactive center of the enzyme to the position at which the catalytic reaction is not affected at all. In general, the reactive center of the enzyme is in the cavity of a three-dimensional structure of an enzyme, which is the same for the artificial enzyme or enzyme disclosed in the invention. The path that a product needs to pass from leaving the reactive center of the enzyme to the position at which the catalytic reaction is not affected at all is at least partially wrapped by some structures. A wrapping degrees are different for different enzymes. Therefore, the path that a product needs to pass from leaving the reactive center of the enzyme to the position at which the catalytic reaction is not affected at all can be understood as a form of “channel”.

As used herein, “the side chain of an amino acid being located in the product release channel” is understood as follows: from the perspective of a three-dimensional structure of the enzyme, the side chains of the amino acid have effect, more or less, on the product release efficiency or catalytic efficiency of the enzyme. For example, if the amino acid is substituted with an amino acid with smaller side chains and the product release efficiency or catalytic efficiency of the enzyme can be increased, then the side chains of the amino acid can be considered to locate in the product release channel.

As a preferred particular embodiment, there are at least 9 amino acids whose side chains are located in product release channel of natural enzyme, and the 9 amino acids are selected from tryptophan, tyrosine, phenylalanine, glutamic acid and methionine. As a preferred particular embodiment, the three-dimensional structure of the natural enzyme at least comprises one β-sheet and one α-helix located at the release channel, 3 of the 9 amino acids are located at β-sheet, and according to the relative positions, the 3 amino acids are phenylalanine at position 353, phenylalanine at position 355 and tryptophan at position 364 respectively; and 6 of the 9 amino acids are located at α-helix, and according to the relative positions, the 6 amino acids are the phenylalanine at position 163, tyrosine at position 214, tyrosine at position 218, tyrosine at position 242, methionine at position 246 and glutamic acid at position 249, respectively.

As used herein, the “according to the relative positions” for the amino acid sequence should be understood as follows: the position number of an amino acid in a sequence only represents the relative position of the amino acid. For example, for the foregoing phenylalanine at position 353 and phenylalanine at position 355, it is only indicated that the positions of the former and the latter differ by 2; if a sequence with x amino acids is added at the N-terminus for the entire protein sequence, according to the absolute positions, the position number of the former is 353+x, and the position number of the latter is 355+x; if a sequence with x amino acids is removed at the N-terminus for the entire protein sequence, according to the absolute positions, the position number of the former is 353−x, and the position number of the latter is 355−x; and according to the relative position, the “phenylalanine at position 353” and the “phenylalanine at position 355” should also be understood to include both cases.

In another aspect, the present invention provides an enzyme, and the enzyme has one or more of the following features:

1) the amino acid sequence of the enzyme includes amino acid sequence with more than 85%, or more than 90%, or more than 95%, or more than 98%, or more than 99% homology to the amino acid sequence shown in SEQ ID NO: 2; or the amino acid sequence of the enzyme includes the amino acid sequence shown in SEQ ID NO: 2; or the amino acid sequence of the enzyme is as shown in SEQ ID NO: 2;

2)the enzyme is encoded by nucleic acid hybridized with complementary chain of nucleic acid encoding protein with an amino acid sequence shown by SEQ ID NO:2 under a high stringent condition; and

3) the amino acid sequence of the enzyme includes the amino acid sequence in which the amino acid sequence as shown in SEQ ID NO: 2 is conservatively substituted; wherein, according to the relative locations, at least one of the amino acids at positions 353, 355 and 364 of the enzyme is a first small-molecular-weight amino acid; at least one of the amino acids at positions 163, 214, 218, 242, 246 and 249 of the enzyme is a second small-molecular-weight amino acid, and the first small-molecular-weight amino acid has a molecular weight less than 140, and the second small-molecular-weight amino acid has a molecular weight less than 110.

As used herein, “being conservatively substituted” should be understood as a substitution of a given amino acid in a polypeptide with another amino acid having similar characteristics. Typically, the following substitutions are considered as conservative substitutions: substituting an aliphatic amino acid such as Ala, Val, Leu, and lie with another aliphatic amino acid; substituting Ser with Thr, and vice versa; substituting acidic residue such as Asp or Glu with another acidic residue; substituting an amide group-containing residue such as Asn or Gin with another amide group-containing residue; substituting a basic residue such as Lys or Arg with another basic residue; and substituting an aromatic residue such as Phe or Tyr with another aromatic residue.

Functionally equivalent amino acids are generally similar to the amino acids to be substituted in size and/or characteristics (e.g., charge or hydrophobicity). Amino acids with similar properties can be grouped as follows:

(1) hydrophobicity: His, Trp, Trp, Tyr, Phe, Met, Leu, Ile, Val, Ala;

(2) neutral hydrophobicity: Cys, Ser, Thr;

(3) polarity: Ser, Thr, Asn, Gln;

(4) acidic/negatively charged: Asp, Glu;

(5) charged: Asp, Glu, Asn, Lys, His;

(6) basic/positively charged: Asn, Lys, His;

(7) basic: Asn, Gln, His, Lys, Arg;

(8) residues affecting chain orientation: Gly, Pro; and

(9) aromatic: Trp, Tyr, Phe, His.

In another aspect, the present invention provides an enzyme, and the enzyme has the activity for catalyzing the conversion reaction from compound I to compound II as shown by the following formula,

or the enzyme is nicotine dehydrogenase;

The enzyme has a product release channel, wherein the amino acid with a side chain at the narrowest site of the product release channel has a molecular weight of less than 140.

As used herein, “the amino acid with side chains located at the narrowest site of the product release channel” should be understood as the amino acid which is blocked most severely in the path that a product needs to pass from leaving the reactive center of the enzyme to the position at which the catalytic reaction is not affected at all.

The present invention will be further described in combination with particular examples.

The materials used herein can be purchased directly unless otherwise specified. The experimental methods used herein are conventional methods in the art unless otherwise specified.

EXAMPLE 1 Cloning, Expression and Purification of Wild-Type Nicotine Dehydrogenase (NicA2) and Nitrogen-Terminal-Truncated NicA2 (NicA2Δ20) 1. Cloning of NicA2

The full-length gene sequence of NicA2 protein was obtained through sequencing by Xuping Research Group, as shown in SEQ ID NO: 4. The full-length sequence of NicA2 was amplified from Pseudomonas putida S16 bacteria solution (CCTCC No. M 205038) with primers NicA2-F1 and NicA2-R1 using a PCR method, and after digested by NcoI and XhoI, ligated into the pET28a vector with 6 histidine tags at the carbon terminal of the vector. Herein, the primer sequences are:

NicA2-F1: 5′-ATACCATGGTGAGTGATAAAACAAAAACAAATGAAG-3′; NicA2-R1: 5′-GTGCTCGAGGCTTAAGAGCTGCTTAACCTCCCTA-3′.

2. Expression of NicA2

After being verified through sequencing, the recombinant plasmid pET28a-NicA2 was transformed into the expression vector E. coli BL21 (DE3), and single colonies were picked for detection of expression. The colonies with protein expression were amplified and cultured at 37° C. and 220 rpm, and when the OD₆₀₀ of the bacteria solution was 0.6-0.8, induction was performed with 0.2 mM isopropyl thiogalactoside at 16° C. for 16 hours.

3. Purification of NicA2

After the induced bacterial solution was centrifuged, the bacteria were collected and resuspended, crushed at 1500 bar, and centrifuged at a high speed, and then the protein in the supernatant was collected by a pre-filled and balanced Ni-NTA gravity column (purchased from Qiagen, Cat. No.30430). Non-specifically bound hetero-proteins were removed with 20 mM and 50 mM imidazole, and the target proteins were eluted with 80 mM, 170 mM, and 300 mM imidazole. The target protein was passed through superdex200 column (purchased from GE, model: 28-9909-44) to remove imidazole, and then centrifuged at a speed of not more than 5000 rpm using a 30 KD ultrafiltration tube (MD), so that the target protein was concentrated to 12 mg/mL for use in spotting. The purified protein was verified by polyacrylamide gel electrophoresis, as shown in FIG. 1, and its purity could be over 90%.

4. Cloning, Expression and Purification of NicA2Δ20

The nitrogen-terminal-truncated NicA (NicA2Δ20) was obtained according to the above cloning, expression and purification methods.

Herein, the primers used for cloning were NicA2-F2 and NicA2-R1, and the obtained recombinant plasmid was pET28a-NicA2Δ20.

NicA2-F2: ATACCATGGCAGTCGTAACAGCAGGTGTTGCGGGA; NicA2-R1: GTGCTCGAGGCTTAAGAGCTGCTTAACCTCCCTA.

EXAMPLE 2 Crystallization and Crystal Diffraction of Wild-Type Nicotine Dehydrogenase (NicA2), Nitrogen-Terminal-Truncated NicA2 (NicA2Δ20), and NicA2Δ20-Nicotine Eutectic 1. Crystallization of NicA2

Crystal cultivation was performed for the NicA2 full-length protein at 14° C. by sitting drop method. 1 uL protein and 1 uL crystallization reagent (lower bath) were mixed for dotting on a 48-well plate using Hampton Research protein crystallization kit (Cat. No. HR2-109). After standing for about one week, crystal growth was observed under a microscope; and after standing for two weeks, crystal growth arrest was observed under the microscope. The crystal growth conditions were: Index-65: 0.1 M Ammonium acetate, 0.1 M BIS-TRIS pH 5.5, 17% w/v Polyethylene glycol 10, 000; Salt RX2-36: 1.4 M Ammonium tartrate dibasic, 0.1 M Tris pH 8.5.

2. Crystal Diffraction of NicA2

The crystals grown under the condition of Index-65 crystallization had almost no diffraction point by X-ray diffraction, and no crystal grew in the repeated experiments, so optimization for this condition was abandoned. For the crystals grown under the SaltRX2-36 crystallization condition, the resolution of X-ray diffraction was about 3 Å, and the diffraction point had a tail, indicating that the crystals grown under this condition had irregular internal stacking.

The optimization for NicA2 full-length protein crystal after primary screening included the optimization through precipitant concentration and optimization through seed addition, but the crystal diffraction obtained was still poor.

3. Crystallization and Crystal Diffraction of NicA2Δ20

After sequence comparison, 20 amino acids with poor conservation were truncated from the N-terminus. Herein, the sequence comparison with nicotine amineoxidase HZN6 (NCBI accession number: AGH68979.1), (S)-6-hydroxy nicotine-oxidase (NCBI accession number: AGS16700.1) and amine oxidase (NCBI accession number: AEJ14619.1) was performed in NCBI.

Purified NicA2Δ20 protein was obtained according to the cloning, expression and purification methods in Example 1, and crystal preliminary screening was carried out as described in the above methods. Crystals with improved shape still appeared in the crystallization reagent of SaltRX2-36: 1.4 M Ammonium tartrate dibasic, 0.1 M Tris pH 8.5. The crystal of NicA2Δ20 was subjected to optimization steps such as the precipitant concentration variation, micro-seeding, and change in ratio of protein and crystallization reagent, etc., to obtain a crystal having an X-ray diffraction resolution of 2.65 Å. Herein, the concentration of the precipitant was optimal at 1.4 M Ammonium tartrate dibasic. The microscopic observation of the crystal was shown in FIG. 2.

4. Selenium Substitution and Crystal Diffraction of NicA2Δ20

After comparison, the amino acid sequence of NicA2Δ20 had a consistency of only 28% with published proteins in Protein Data Bank (PDB). The NicA2 structure could not be analyzed by simple molecular replacement, so the phase was determined by purifying selenium substituted protein and according to the anomalous scattering of selenium atoms in the self-amino acid, furthermore the structure was analyzed. The recombinant plasmid pET28a-NicA2Δ20 was transformed into the host E. coli B834 (DE3), and the selenium substituted protein was purified by the method in Example 1. The host was a methionine-deficient strain. In an inorganic salt medium, using glucose and yeast inorganic nitrogen sources as nutrients, selenomethionine was added to substitute normal methionine, so seleno-NicA2, i.e. SeMet-NicA2Δ20 could be expressed. The specific expression and purification steps of SeMet-NicA2Δ20 were described in Example 1. After crystal primary screening, SeMet-NicA2Δ20 had crystals with superior appearance in the condition of SaltRX2-36:1.4 M Ammonium tartrate dibasic, 0.1 M Tris pH 8.5. After optimization through the ratio of crystal protein to precipitant, the crystal having an X-ray diffraction resolution of 2.25 Å was obtained.

5. Crystallization and Crystal Diffraction of NicA2Δ20-nicotine Eutectic

NicA2Δ20-nicotine eutectic was obtained by soaking NicA2Δ20 protein crystal in a higher concentration of nicotine solution. The pure nicotine was diluted by a crystal growth buffer (the composition of the buffer as described above) to form a 1 M nicotine mother solution and pH was adjusted to 8.5. The sodium hydrosulfite was dissolved in a crystal growth buffer to 100 mM, and pH was adjusted to 7.0 to form a mother liquor of sodium hydrosulfite. The final concentration of nicotine was 10 mM, and the final concentration of the sodium hydrosulfite was 20 mM in a mixed buffer for soaking crystals. Of which, the sodium hydrosulfite solution produced an oxygen-free environment. The crystal with the best crystal form was taken and quickly soaked into the mixed solution of nicotine and sodium hydrosulfite for 30 seconds, to quickly capture the instant during which NicA2 was bound with the substrate nicotine. The crystals after soaked in nicotine were quickly frozen in liquid nitrogen. Finally, a NicA2Δ20-nicotine crystal having an X-ray diffraction resolution of 2.5 A was obtained.

EXAMPLE 3 Structure Elucidation and Analysis of Nicotine Dehydrogenase NicA2 1. Structure Elucidation of NicA2Δ20

The X-ray diffraction data of the SeMet-NicA2Δ20 crystal obtained in Example 2 was processed by software HKL2000, and the structure of SeMet-NicA2Δ20 was preliminarily elucidated by the phenix program. Using the seleno structure as a template and through isomorphous replacement, the crystal structure was refined by the programs coot and ccp4, and finally the structure of NicA2Δ20 was elucidated.

2. Structural Elucidation of NicA2Δ20-Nicotine Crystal

For the NicA2Δ20-nicotine crystal obtained in Example 2, using the previously elucidated NicA2Δ20 structure as a model and through the molecular replacement method, the structure of NicA2Δ20 and substrate nicotine eutectic was finally elucidated, as shown in FIG. 3.

3. Structural Analysis

In the article Crystallographic snapshots of the complete reaction cycle of nicotine degradation by an amine oxidase of the monoamine oxidase (MAO) family published in PNAS in 2011, the structure of the first dehydrogenase 6-hydroxy-1-nicotine dehydrogenase (6HLNO) in the metabolic nicotine pathway was elucidated in another strain that can efficiently degrade nicotine, and the channels for the substrate 6-hydroxy-nicotine into the catalytic site and releasing the product 6-hydroxy-N-methylmyosmine and 6-hydroxy- pseudooxynicotine were analyzed.

Based on this finding, the amino acid sequences of NicA2 and 6HLNO were compared (NCBI registration No.: YP_007988777.1). Even though the similarity of amino acid sequences is only 28%, the crystal structure of NicA2Δ20 has a certain similarity with the previously reported structure of 6HLNO structure in the Arthrobacter sp. nicotine degradation pathway, and the two also differ significantly. The most obvious difference is that diacylglycerol phospholipid is bound to 6HLNO, but this phenomenon does not exist for NicA2Δ20. The a3a and a3b spirals of NicA2Δ20 have a 45-degree rotation compared to the corresponding spiral on 6HLNO. These two α-helixes directly face to the nicotine-binding region, so that NicA2Δ20 has a more tightly packing degree for the substrate nicotine than 6HLNO does for its substrate 6-hydroxy-1-nicotine (6HLN), i.e. the loss of lipid molecules causes NicA2Δ20 to form a more compact structure, such that its nicotine-degrading products of N-methymyosmine and pseudooxynicotine are constrained in a narrow active site pocket within NicA2Δ20.

According to the report of pseudooxynicotine in PNAS (Galina Kachalova et. al, Crystallographic snapshots of the complete reaction cycle of nicotine degradation by an amine oxidase of the monoamine oxidase (MAO) family, [J] PNAS, 108 (12): 4800-4805), the corresponding product release channel is found in the NicA2Δ20 structure. Interestingly, the substrate nicotine is completely embedded inside the NicA2Δ20. No trace of nicotine can be found when looking inward either from the channel for substrate incoming or from the product release channel (as shown in a of FIG. 3). Only when the surface gray level of NicA2Δ20 is adjusted to transparency, the nicotine is observed to be deeply embedded in the pocket of the active site (as shown in b of FIG. 3). Through careful analysis of the product release channel, it is found that this channel is blocked by 9 large amino acids: W364 (tryptophan), Y214 (tyrosine), Y218 (tyrosine), F355 (phenylalanine), F353 (phenylalanine), E249 (glutamic acid), F163 (phenylalanine), M246 (methionine) and Y242 (tyrosine) (as shown in b and c of FIG. 3). Therefore, it is speculated that this extremely restraining channel is likely to strongly block the release of the product pseudooxynicotine from NicA2Δ20.

In addition, full-wavelength scanning experiments and gas chromatography (GC) experiments have shown that the characteristics of “complete embedding” and “extreme binding” of NicA2 structure greatly hinder the release of pseudooxynicotine. Herein, the full-wavelength scanning experiments prove that the nicotine can be quickly dehydrogenated under the catalysis of NicA2, and the gas chromatography (GC) experiments prove that the product pseudooxynicotine is released from NicA2 very slowly.

In previous experiments, it is observed that when equimolar substrate nicotine is added to 1 mL of 10 mg/mL NicA2 protein solution, the bright yellow color of the NicA2 protein solution instantly becomes colorless and transparent. In view of that the prosthetic group of NicA2 is FAD and the function of NicA2 is catalytic dehydrogenation of nicotine, it can be considered that an instant process that NicA2 catalyzes the dehydrogenation of nicotine and transfers hydrogen to FAD to oxidize it to form FADH2. That is, the reaction of dehydrogenation of nicotine into pseudooxynicotine is rapidly catalyzed by NicA2. The UV-Scan experiments showed that, after the addition of nicotine to NicA2 solution, the FAD characteristic ultraviolet absorption peaks (375 mm, 450 mm) disappears quickly. Subsequently, gas chromatography was used to detect the total amount of pseudooxynicotine and the amount of pseudooxynicotine released outside of protein after an equimolar amount of nicotine was added to 1 ml of 10 mg/mL NicA2 solution and reaction was performed for 1.5 hours.

Herein, the pseudooxynicotine was extracted with chloroform-benzyl alcohol for the sample after 1.5 hours of reaction, and the total amount of produced nicotine was quantitatively detected by GC. After repeatedly passing through Ni-NTA column, the NicA2 was considered to be completely bound with the nickel column when the concentration of NicA2 in effluent was detected to be lower than 0.1 mg/mL. The pseudooxynicotine in the effluent was extracted with chloroform-benzyl alcohol, and the amount of pseudooxynicotine released from the NicA2 into solution was quantitatively determined by GC. The results showed that approximately 75% of the pseudooxynicotine remained in the NicA2 protein.

EXAMPLE 4 Construction of a Nicotine Dehydrogenase Mutant

The positions of the nine large amino acids obtained in Example 3 on the crystal structure of NicA2Δ20 were analyzed, and the amino acid located on the β-sheet was replaced with valine (Vine, V), and the amino acids located on the α-helix were replaced with alanine (Alanine, A). The basic principle for amino acid substitution is to replace the amino acid with a large side chain group with an amino acid having a side chain group as small as possible, at the same time, it should be considered that alanine was the simplest amino acid structure and is also a strong α-helix-maker and the structure of valine is also very simple and is also a strong β-sheet-maker. Finally, F163, Y214, Y218, Y242, M246 and E249 were mutated to alanine, and F353, F355V and W364V were mutated to valine, and the mutant was named as NicA2-M9. By designing the mutated DNA sequence, the above mutation was achieved. The DNA sequence after mutation was shown in SEQ ID NO: 3.

The gene sequence of the above nicotine dehydrogenase mutant NicA2-M9 was synthesized by GENEWIZ Corporation. The synthesized sequence was amplified by a PCR method, and the primers used for amplification were NicA2-F1 and NicA2-R1.

The mutant gene fragment and the vector pET28a obtained by amplification were digested with NcoI and XhoI, and ligated with T4 to obtain a recombinant plasmid pET28a-NicA2-M9. After the recombinant plasmid was sequenced and the sequencing result showed a correct sequence, the plasmid was transformed into the host E. coli BL21 (DE3) for expression. The purification process of the expressed nicotine dehydrogenase mutant NicA2-M9 was carried out with reference to the wild type NicA2 protein purification method in Example 1.

Samples were taken after the processes of bacteria lysis, the supernatant, precipitate, and column effluent during the purification, 20 mM imidazole, 50 mM imidazole for removing impurity protein and 170 mM imidazole for eluting target protein, and detected by polyacrylamide gel electrophoresis. The results were shown in FIG. 4. The NicA2-M9 protein had a good abundance and the purity was more than 90%, which could meet the requirements of subsequent enzyme activity experiments.

EXAMPLE 5 Determination and Comparison of Enzyme Activities of Wild-Type Nicotine Dehydrogenase and Nicotine Dehydrogenase Mutants

The enzyme activities of the wild type NicA2 and the NicA2 mutant NicA2-M9 were labeled by detecting the amount of the products N-methymyosmine and pseudooxynicotine by using liquid chromatography-mass spectrometry (LC-MS). The LC-MS parameters were as follows: Agilent 1290 LC, EC-C8 column (4.6×100 mm, 1.8 um), and 0.2 mL/min. Under the positive ion mode, the nucleoplasmic ratio (m/z) of N-methymyosmine was 161 and the nucleoplasmic ratio (m/z) of pseudooxynicotine was 179.

The N-methymyosmine and pseudooxynicotine were diluted from the highest concentration of 2 uM to the lowest concentration of 31.25 nM through tiraes ratio dilution, and were loaded to an LC-MS instrument, and the peaks with nucleoplasmic ratios of 161 and 179 were selected. The area of the peak automatically annotated from the instrument was recorded. The standard curves of the two products were plotted using the software OriginPro8.

1. Determination of Wild-type Nicotine Dehydrogenase Activity

The final concentration of the immobilized NicA2 wild-type protein was 10 nM, and the concentration of the substrate nicotine was diluted from the highest concentration of 2 uM to the lowest concentration of 12.5 nM. The protein and substrate were incubated at 30° C. for 20 minutes, and the reaction was inactivated by 2.5 times volume of acetonitrile. The protein precipitate was removed by centrifuging for 2 min at 12,000 rpm, and the obtained sample was loaded to a LC-MS instrument. The peaks with nucleoplasmic ratios at 161 and 179 were selected, and the peak area automatically annotated from the instrument was recorded. The Michaelis-Menten equation curve was plotted by OriginPro 8, as shown in FIG. 5 and FIG. 6.

The K_(m) and k_(cat) values for producing N-methylmyosmine and pseudooxynicotine by reaction through NicA2 wild-type nicotine was calculated by combining the standard curve of the product. The K_(m) and k_(cat) values for producing N-methylmyosmine by reaction through NicA2 wild-type nicotine reaction were 24.24 nM and 6.17×10⁻³/s, respectively; and the K_(m) and k_(cat) values for producing pseudooxynicotine were 19.71 nM and 13.75×10⁻³/s, respectively.

2. Determination of Nicotine Dehydrogenase Mutant Enzyme Activity

The determination method of nicotine dehydrogenase mutant NicA2-M9 enzyme activity was the same as that of wild type NicA2 enzyme activity. The final concentration of immobilized NicA2-M9 protein was 10 nM, and the concentration of substrate nicotine was diluted from the highest concentration of 2 uM to the lowest concentration of 12.5 nM through tiraes ratio dilution. The protein and substrate were incubated at 30° C. for 20 minutes, and the reaction was inactivated by 2.5 times volume of acetonitrile. The protein precipitate was removed by centrifuging for 2 min at 12,000 rpm, and the obtained sample was loaded to a LC-MS instrument. The peaks with the nucleoplasmic ratios of 161 and 179 were selected, and the peak area automatically annotated from the instrument was recorded. The Michaelis-Menten equation curve was plotted by OriginPro 8, as shown in FIG. 7 and FIG. 8.

Based on the standard curve of the product, the K_(m) and k_(cat) values for producing N-methylmyosmine and pseudooxynicotine by catalyzing nicotine with NicA2-M9 were calculated. The K_(m) and k_(cat) values for producing N-methylmyosmine by catalyzing nicotine with NicA2-M9 were 46.61 nM and 23.20×10⁻³/s, respectively.

3. Comparison

Table 1 shows the K_(m) and k_(cat) values for producing N-methylmyosmine and pseudooxynicotine by catalyzing substrate with wild type NicA2 and NicA2-M9. By comparison, it shows that the K_(m) for producing N-methylmyosmine by NicA2-M9 catalysis is 1.96 times of that of wild type NicA2, and the K_(m) for producing pseudooxynicotine by NicA2-M9 catalysis is 2.5 times of that of wild type NicA2. However, the k_(cat) for producing N-methylmyosmine by NicA2-M9 catalysis is 3.76 times of that of wild type NicA2, and the k_(cat) for producing pseudooxynicotine by NicA2-M9 catalysis is 3.67 times of that of wild type NicA2, which further demonstrates that the substitution of a bulky amino acid with an amino acid with simple side chains can effectively accelerate the release of the product pseudooxynicotine and increase the efficiency of the reaction.

Table 1 The reaction rate constants for catalyzing nicotine reactions with NicA2 wild-type and NicA2 mutants

m/z 161 m/z 179 K_(m) NicA2 wild type 24.24 nM 19.71 nM NicA2 mutant 46.61 nM 50.20 nM k_(cat) NicA2 wild type  6.17 × 10⁻³/s 13.75 × 10⁻³/s NicA2 mutant 23.20 × 10⁻³/s 50.48 × 10⁻³/s

EXAMPLE 6 Comparative Analysis of Nicotine Dehydrogenase Mutant Properties and Blood Concentration of Nicotine

The results of Example 5 indicates that the rate for catalyzing nicotine by NicA2-M9 is much higher than that of NicA2 wild-type protein, while the affinity of NicA2-M9 for nicotine is slightly weaker than that of NicA2 wild-type protein. Subsequently, the affinity of NicA2-M9 for nicotine (K_(m)) is compared with the concentration of nicotine in the blood. As shown in Table 3, it is found that even if NicA2-M9 has a slightly weaker affinity for nicotine than wild type NicA2, the K_(m) of catalyzing nicotine by NicA2-M9 is lower than most concentrations of nicotine in the blood.

Table 2 The affinity of NicA2 mutant for nicotine and the highest concentration of nicotine in the blood

Affinity of NicA2 mutant The highest concentration for nicotine (K_(m)) of nicotine in the blood 96.81 nM 162 nM-370 nM

EXAMPLE 7 Modification of Original Metabolic Pathway by Nicotine Dehydrogenase Mutant

The wild type NicA2 and NicA2-M9 gene sequences were ligated into shuttle plasmid pME6032 to obtain pME6032-NicA2 plasmid and pME6032-NicA2-M9 plasmid. Herein, the pME6032 plasmid can respond well to the induction of isopropylthiogalactoside. The recombinant plasmid was transformed into Pseudomonas putida S16 through electroporation, and simultaneously into the empty pME6032 plasmid and the pME6Q32-NicA2-M9+pNAO plasmid ligated with NicA2-M9 gene sequences and recombinant fragments of protein pseudooxynicotine AO gene sequences whose downstream catalyzes pseudooxynicotine (pseudooxynicotine AO can efficiently catalyze pseudooxynicotine), which were used as two groups of controls, respectively.

Pseudomonas putida S16 transformed with the above four plasmids was cultured in an inorganic salt medium containing nicotine as the sole carbon and nitrogen source, and when the OD₆₀₀ value was 0.6, 3 mg/mL nicotine and 0.8 mM isopropylthiogalactoside were added to induce protein expression. 2 mL of bacterial supernatant induced for each sample for 0-5 hours was collected, after lyophilization, the pseudooxynicotine was extracted with benzyl alcohol-chloroform and loaded into a gas chromatograph. The amount of pseudooxynicotine was measured by a pseudoxynicotine standard curve drawn previously.

As shown in FIG. 9, the experimental results demonstrates that, compared with the cases of transformation into pME6032 empty plasmid and pME6032-NicA2 plasmid through electroporation, the case of transformation into the pME6032-NicA2-M9 plasmid through electroporation (i.e. as shown in s16(NicA2-9 MT) in FIG. 9) shows significantly increase in the release amount of pseudooxynicotine. When NicA2-M9 is recombined with pseudooxynicotine AO (i.e. as shown in s16(NicA2-9 MT+pNAO) in FIG. 9), the pseudooxynicotine AO degrades the pseudooxynicotine, which significantly reduces the release amount of pseudooxynicotine. It further confirms that the increased release amount of pseudooxynicotine is caused by modification of NicA2 protein.

EXAMPLE 8

Similar to Example 4, the positions of the nine large amino acids obtained in Example 3 on the crystal structure of NicA2Δ20 were analyzed, and the following mutations were made:

(1) F353, F355 and W364 were mutated to valine, and the mutant was named as NicA2-M3V;

(2) F353, F355 and W364 were mutated to alanine, and the mutant was named as NicA2-M3A;

(3) F353, F355 and W364 were mutated to valine, Y214 and Y218 were mutated to alanine, and the mutant was named as NicA2-M5; and

(4) F353, F355 and W364 were mutated to valine, Y214, Y218, F163 and E249 were mutated to alanine, and the mutant was named as NicA2-M7.

As can be seen from A of FIG. 10, the product release channel of wild-type NicA2 is blocked by the nine large amino acids described above. For the various combinations of mutations for the nine large amino acids, as shown from FIG. 10, the product release channels of NicA2-M3V mutant (B), NicA2-M3A mutant (C), NicA2-M5 mutant (D), NicA2-M7 mutant (E) and NicA2-M9 mutant (F) are broadened to varying degrees.

EXAMPLE 9

Similar to Example 4, the positions of the nine large amino acids obtained in Example 3 on the crystal structure of NicA2420 were analyzed, and the following mutations were made:

(1) F353, F355 and W364 were mutated to glycine, F163, Y214, Y218, Y242, M246 and E249 were mutated to alanine, and the mutant was named as NicA2-M3G6A;

(2) F353, F355, W364 and E249 were mutated to glycine, F163, Y214, Y218, Y242 and M246 were mutated to alanine, and the mutant was named as NicA2-M4G5A;

(3) F353, F355, W364, E249 and M246 were mutated to glycine, F163, Y214, Y218 and Y242 were mutated to alanine, and the mutant was named as NicA2-M5G4A;

(4) F353, F355 and W364 were mutated to proline, F163, Y214, Y218, Y242, M246 and E249 were mutated to alanine, and the mutant was named as NicA2-M3P6A;

(5) F353, F355, W364 and E249 were mutated to proline, F163, Y214, Y218, Y242 and M246 were mutated to alanine, and the mutant was named as NicA2-M4P5A;

(6) F353, F355, W364, E249 and M246 were mutated to proline, F163, Y214, Y218 and Y242 were mutated to alanine, and the mutant was named as NicA2-M5P4A;

(7) F353, F355 and W364 were mutated to serine, F163, Y214, Y218, Y242, M246 and E249 were mutated to alanine, and the mutant was named as NicA2-M3S6A;

(8) F353, F355, W364 and E249 were mutated to serine , F163, Y214, Y218, Y242 and M246 were mutated to alanine, and the mutant was named as NicA2-M4S5A;

(9) F353, F355, W364, E249 and M246 were mutated to serine, F163, Y214, Y218 and Y242 were mutated to alanine, and the mutant was named as NicA2-M5S4A;

(10) F353, F355 and W364 were mutated to threonine, F163, Y214, Y218, Y242, M246 and E249 were mutated to alanine, and the mutant was named as NicA2-M3T6A;

(11) F353, F355, W364 and E249 were mutated to threonine, F163, Y214, Y218, Y242 and M246 were mutated to alanine, and the mutant was named as NicA2-M4T5A;

(12) F353, F355, W364, E249 and M246 were mutated to threonine, F163, Y214, Y218 and Y242 were mutated to alanine and the mutant was named as NicA2-M5T4A.

As can be seen from FIG. 11, compared with the product release channel of wild-type NicA2 (A in FIG. 11), the product release channels of the NicA2-M3G6A mutant (G), the NicA2-M4G5A mutant (H), the NicA2-M5G4A mutant (I), the NicA2-M3P6A mutant (J), the NicA2-M4P5A mutant (K), the NicA2-M5P4A mutant (L), the NicA2-M3S6A mutant (M), the NicA2-M4S5A mutant (N), the NicA2-M5S4A mutant (O), the NicA2-M3T6A mutant (P), the NicA2-M4T5A mutant (Q) and the NicA2-M5T4A mutant (R) are broadened to varying degrees.

The product release channel of wild-type NicA2 shown in A of FIG. 11 differs from that shown in A of FIG. 10. This is because the structure of the protein is stereoscopic and the cross-sectional views of the protein structure viewed from different angles are different, and the shown cross-sectional views of the product release channel are also different. Since A in FIG. 11 and A in FIG. 10 show cross-sectional views of the protein structure viewed from different angles, the cross-sectional views of the product release channel eventually shown by the two are different. In this case, the protein structures of wild-type NicA2 (A) in FIG. 10 and all the mutants (from B to F) in FIG. 10 are observed from the same angle; and the protein structures of wild-type NicA2 (A) in FIG. 11 and all the mutants (from G to R) in FIG. 11 are observed from the same angle.

As can be seen from Example 8 and 9, the product release channels of the NicA2 mutants (from B to R), when compared with wild-type NicA2, are broadened to varying degrees. In combination with the above related activity experiments for the NicA2-M9 mutant, those skilled in the art will appreciate that, when the large amino acids that block product release are replaced with small amino acids for the above mutations, it can accelerate the product release and improve the reaction efficiency.

It will also be apparent to those skilled in the art that, as long as large amino acids that block product release are partially or wholly replaced by smaller amino acids, it can improve the product release rate for NicA2. The mutations listed in the examples are merely illustrative.

EXAMPLE 10 Commonality of Phenomenon That Nicotine Dehydrogenase Contains 9 Large Amino Acids That Hinder the Release of Substrates Among Members of the Monoamine Oxidase Family

The amino acid sequence of NicA2 was compared with the amino acid sequence of 10 amino acids including monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) in the monoamine oxidase family using the sequence comparison software Vector NTI, and the results were shown in FIG. 12. It was found that the nine large amino acids in NicA2 that blocked the release of the substrate had certain conservation in family members (as shown in the arrows in FIG. 12). The amino acid comparison revealed that amino acids in family members corresponding to the nine large amino acids in NicA2 that blocked the release of the substrate were almost amino acids with bulky side chains.

The structural analysis suggests that their substrates are also embedded in the “cave” consisting of aromatic amino acids, which is very similar to NicA2 (J. Mol. Biol. 338, 103-114; Proc. Natl. Acad. Sci. USA 100, 9750-9755). Base on the above content, we can reasonably explain the phenomenon of blockage by large amino acids in the monoamine oxidase A and monoamine oxidase B product channels. Monoamine oxidase is a mitochondrial transmembrane protein that is responsible for the transmission of neurotransmitters. The important substrate for monoamine oxidase A is serotonin, and the oxidase A catalyzes the further conversion of serotonin to melatonin. It is worth noting that serotonin has high content in cerebral cortex and synapses, which can excite the body, while melatonin is a tranquilizer and a substance that induces sleep; the important substrate for monoamine oxidase B is tetrahydropyridine, and its catalysis product is a neurotoxin that generates Parkinson's disease.

Similar to NicA2, the substrates for monoamine oxidase A and monoamine oxidase B and especially the products are tiny but functionally important small molecules. It is conceivable that the embedding of product release channel with large amino acids by proteins is actually a controllable release mechanism for the product.

The preferred embodiments of the present invention have been described in detail above. Those skilled in the art can make many modifications and variations without creative work according to the conception of the invention. Therefore, any technical solution that can be obtained by those skilled in the art based on the prior art by logic analysis, reasoning or limited experimentation should be within the scope of protection determined by the appended claims. 

1. An artificial enzyme, wherein the artificial enzyme is produced based on modification of a sequence of a natural enzyme and has nicotine dehydrogenase activity, the natural enzyme having an amino acid sequence as shown in SEQ ID NO: 1, wherein the modification is substituting one or more of phenylalanine at position 353, phenylalanine at position 355, tryptophan at position 364, phenylalanine at position 163, tyrosine at position 214, tyrosine at position 218, tyrosine at position 242, methionine at position 246 and glutamic acid at position 249 of the amino acid sequence SEQ ID NO: 1 with same or different amino acids with smaller side chains.
 2. The artificial enzyme as in claim 1, wherein molecular weights of the amino acids with smaller side chains are less than
 140. 3. The artificial enzyme as in claim 1, wherein the molecular weights of the amino acids with smaller side chains are less than
 120. 4. The artificial enzyme as in claim 1, wherein the amino acids with smaller side chains are selected from a group consisting of alanine, valine, glycine, proline, serine and threonine.
 5. The artificial enzyme as in claim 1, wherein the amino acids with smaller side chains are alanine or valine.
 6. The artificial enzyme as in claim 1, wherein the modification is substituting one or more of phenylalanine at position 353, phenylalanine at position 355 and tryptophan at position 364 of the amino acid sequence SEQ ID NO: 1 with a first small-molecular-weight amino acid, and/or substituting one or more of phenylalanine at position 163, tyrosine at position 214, tyrosine at position 218, tyrosine at position 242, methionine at position 246 and glutamic acid at position 249 of the amino acid sequence SEQ ID NO: 1 with a second small-molecular-weight amino acid, wherein molecular weights of the first small-molecular-weight amino acid and the second small-molecular-weight amino acid are less than
 140. 7. The artificial enzyme as in claim 6, wherein the molecular weights of the first small-molecular-weight amino acid and the second small-molecular-weight amino acid are less than
 120. 8. The artificial enzyme as in claim 6, wherein the first small-molecular-weight amino acid is alanine, valine, glycine, proline, serine or threonine, and the second small-molecular-weight amino acid is alanine.
 9. The artificial enzyme as in claim 6, wherein the first small-molecular-weight amino acid is alanine or valine, and the second small-molecular-weight amino acid is alanine.
 10. The artificial enzyme as in claim 1, wherein the modification is substituting one or more of phenylalanine at position 353, phenylalanine at position 355 and tryptophan at position 364 of the amino acid sequence SEQ ID NO: 1 with valine, and/or substituting one or more of phenylalanine at position 163, tyrosine at position 214, tyrosine at position 218, tyrosine at position 242, methionine at position 246 and glutamic acid at position 249 of the amino acid sequence SEQ ID NO: 1 with alanine.
 11. The artificial enzyme as in claim 1, wherein the modification is substituting one or more of phenylalanine at position 353, phenylalanine at position 355 and tryptophan at position 364 of the amino acid sequence SEQ ID NO: 1 with glycine, and/or substituting one or more of phenylalanine at position 163, tyrosine at position 214, tyrosine at position 218, tyrosine at position 242, methionine at position 246 and glutamic acid at position 249 of the amino acid sequence SEQ ID NO: 1 with alanine or glycine.
 12. The artificial enzyme as in claim 1, wherein the modification is substituting one or more of phenylalanine at position 353, phenylalanine at position 355 and tryptophan at position 364 of the amino acid sequence SEQ ID NO: 1 with proline, and/or substituting one or more of phenylalanine at position 163, tyrosine at position 214, tyrosine at position 218, tyrosine at position 242, methionine at position 246 and glutamic acid at position 249 of the amino acid sequence SEQ ID NO: 1 with alanine or proline.
 13. The artificial enzyme as in claim 1, wherein the modification is substituting one or more of phenylalanine at position 353, phenylalanine at position 355 and tryptophan at position 364 of the amino acid sequence SEQ ID NO: 1 with serine, and/or substituting one or more of phenylalanine at position 163, tyrosine at position 214, tyrosine at position 218, tyrosine at position 242, methionine at position 246 and glutamic acid at position 249 of the amino acid sequence SEQ ID NO: 1 with alanine or serine.
 14. The artificial enzyme as in claim 1, wherein the modification is substituting one or more of phenylalanine at position 353, phenylalanine at position 355 and tryptophan at position 364 of the amino acid sequence SEQ ID NO: 1 with threonine, and/or substituting one or more of phenylalanine at position 163, tyrosine at position 214, tyrosine at position 218, tyrosine at position 242, methionine at position 246 and glutamic acid at position 249 of the amino acid sequence SEQ ID NO: 1 with alanine or threonine.
 15. The artificial enzyme as in claim 1, wherein the modification is substituting all of phenylalanine at position 353, phenylalanine at position 355 and tryptophan at position 364 of the amino acid sequence SEQ ID NO: 1 with glycine, and/or substituting all of phenylalanine at position 163, tyrosine at position 214, tyrosine at position 218, tyrosine at position 242, methionine at position 246 and glutamic acid at position 249 of the amino acid sequence SEQ ID NO: 1 with alanine.
 16. The artificial enzyme as in claim 1, wherein the modification is substituting all of phenylalanine at position 353, phenylalanine at position 355 and tryptophan at position 364 of the amino acid sequence SEQ ID NO: 1 with proline, and/or substituting all of phenylalanine at position 163, tyrosine at position 214, tyrosine at position 218, tyrosine at position 242, methionine at position 246 and glutamic acid at position 249 of the amino acid sequence SEQ ID NO: 1 with alanine.
 17. The artificial enzyme as in claim 1, wherein the modification is substituting all of phenylalanine at position 353, phenylalanine at position 355 and tryptophan at position 364 of the amino acid sequence SEQ ID NO: 1 with serine, and/or substituting all of phenylalanine at position 163, tyrosine at position 214, tyrosine at position 218, tyrosine at position 242, methionine at position 246 and glutamic acid at position 249 of the amino acid sequence SEQ ID NO: 1 with alanine.
 18. The artificial enzyme as in claim 1, wherein the modification is substituting all of phenylalanine at position 353, phenylalanine at position 355 and tryptophan at position 364 of the amino acid sequence SEQ ID NO: 1 with threonine, and/or substituting all of phenylalanine at position 163, tyrosine at position 214, tyrosine at position 218, tyrosine at position 242, methionine at position 246 and glutamic acid at position 249 of the amino acid sequence SEQ ID NO: 1 with alanine.
 19. A nucleic acid, the nucleic acid encoding the artificial enzyme as in claim
 1. 20. Application of the artificial enzyme as in claim 1 in the preparation of a drug for treating nicotine addiction. 